CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 3,149,640	$ 7,151,800
Accounts receivable, net of allowance for credit losses of $75,000 at March 31, 2024 and September 30, 2023, respectively	408,853	255,502
Inventories	335,943	330,027
Prepaid expenses and other current assets	470,284	389,241
Total current assets	4,364,720	8,126,570
Property and equipment, net	367,821	838,270
Other assets:
Restricted cash	750,000	750,000
Intangible assets	2,698,975	2,698,975
Operating right of use asset	994,111	1,237,762
Total assets	9,175,627	13,651,577
Current liabilities:
Accounts payable and accrued liabilities	2,050,035	2,270,388
Operating lease liability, current	521,719	498,598
Deferred revenue	51,285	76,435
Total current liabilities	2,623,039	2,845,421
Long term accrued liabilities	31,467	31,467
Deferred revenue, long term	194,000	194,000
Operating lease liability, long term	472,391	739,162
Deferred tax liability, net	684,115	684,115
Warrants classified as a liability	5,346,000	4,285,000
Total liabilities	9,351,012	8,779,165
Commitments and contingencies (Note G)
Applied DNA Sciences, Inc. stockholders' (deficit) equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of March 31, 2024 and September 30, 2023, 863,068 and 682,926 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively	864	683
Additional paid in capital	308,206,796	307,397,623
Accumulated deficit	(308,255,808)	(302,447,147)
Applied DNA Sciences, Inc. stockholders' (deficit) equity	(48,148)	4,951,159
Noncontrolling interest	(127,237)	(78,747)
Total (deficit) equity	(175,385)	4,872,412
Total liabilities and (deficit) equity	9,175,627	13,651,577
Series A Preferred stock
Applied DNA Sciences, Inc. stockholders' (deficit) equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively
Series B Preferred stock
Applied DNA Sciences, Inc. stockholders' (deficit) equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively